Reversal of neuromuscular blockade with sugammadex in patients with myasthenia gravis

Boer, Hans D. de; Shields, M.; Booij, L.H.D.J.

doi:10.1097/eja.0000000000000153

Cited by 35 publications

(16 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, anticholinesterases have unfavourable drawbacks (hypersalivation, bradycardia, bronchoconstriction, nausea, vomiting, and abdominal cramps) that can be overcome through co‐administration of antimuscarinic agents (atropine or glycopyrrolate). Meanwhile, antimuscarinics also have unfavourable side effects like dry mouth, tachycardia, and blurred vision . Moreover, anticholinesterases are not capable of reversing deeper levels of NMB …”

mentioning

confidence: 99%

See 1 more Smart Citation

A comparison of sugammadex and neostigmine for reversal of rocuronium‐induced neuromuscular blockade in children

Ammar¹,

Mahmoud²,

Kasemy³

2017

Acta Anaesthesiol Scand

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

“…Meanwhile, antimuscarinics also have unfavourable side effects like dry mouth, tachycardia, and blurred vision . Moreover, anticholinesterases are not capable of reversing deeper levels of NMB …”

mentioning

confidence: 99%

A comparison of sugammadex and neostigmine for reversal of rocuronium‐induced neuromuscular blockade in children

Ammar¹,

Mahmoud²,

Kasemy³

2017

Acta Anaesthesiol Scand

View full text Add to dashboard Cite

show abstract

“…The use of sugammadex in patients with MG has been described in three different publications in 2010. In these studies, a faster reversion was demonstrated without post-operative complications and with hospital discharge in a short period of time after surgery 22,24,33 .…”

Section: Balanced General Anesthesiamentioning

confidence: 89%

Perioperative management of the patient with Myasthenia gravis

Ortíz-Benítez

Carrillo‐Torres

Mendoza-Escoto

et al. 2019

HGMX

View full text Add to dashboard Cite

Myasthenia gravis is an autoimmune disease in which autoantibodies interact postsynaptic nicotinic acetylcholine at the neuromuscular junction which decreases the capacity of the terminal plate to transmit the nerve signal. For the anesthesiologist may be difficult extubation at the end of the procedure, especially if interference drugs are used at the neuromuscular junction. This review addresses the steps to be followed in perioperative management with flowcharts.

show abstract

“…The rocuronium-sugammadex combination has been studied mainly in patients with myasthenia gravis. De Boer et al [51] have published the largest case series (n=21) of patients with myasthenia gravis presenting an Osserman class II (n=13) or class III (n=8) receiving steroidal muscle relaxants followed by sugammadex. At the end of surgery, 2 or 4 mg kg -1 sugammadex were administered to reverse moderate or deep NMB, respectively.…”

Section: Advantages Of Sugammadex In Patients With Comorbidities Patimentioning

confidence: 99%

A Short Update on Sugammadex with a Special Focus on Economic Assessment of its Use in North America

Zaouter¹,

Mion²,

Palomba³

et al. 2017

J Anesth Clin Res

View full text Add to dashboard Cite

Sugammadex offers significant advantages over the current anticholinesterase reversal drugs. Sugammadex used has been approved for the United Stated and for Canada since December 2015 and February 2016, respectively. The present article aims to provide a straightforward and concise review of the most recent literature describing its clinical advantages in routine use. A thorough and cost-effective evaluation has been conducted specifically for North America to determine if its price justifies its inclusion into regular patients' care. The search examined the relevant literature from January 2013 to October 2016. The present narrative review describes how sugammadex could play a crucial role in the modern conduct of anesthesia. The particular emphasis on sugammadex cost-effective analysis performed in this article suggests that this new reversal agent should be considered for a wider use in North America.

show abstract

Reversal of neuromuscular blockade with sugammadex in patients with myasthenia gravis

Cited by 35 publications

References 33 publications

A comparison of sugammadex and neostigmine for reversal of rocuronium‐induced neuromuscular blockade in children

A comparison of sugammadex and neostigmine for reversal of rocuronium‐induced neuromuscular blockade in children

Perioperative management of the patient with Myasthenia gravis

A Short Update on Sugammadex with a Special Focus on Economic Assessment of its Use in North America

Contact Info

Product

Resources

About